CLINICAL TRIALS PROFILE FOR HABITROL

All Clinical Trials for HABITROL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00851357 ↗	Telephone Counseling and the Distribution of Nicotine Patches to Smokers	Completed	California Department of Health Services	Phase 3	2009-02-01	The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00851357 ↗	Telephone Counseling and the Distribution of Nicotine Patches to Smokers	Completed	University of California, San Diego	Phase 3	2009-02-01	The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1. Test if sending active nicotine patches directly will lead to a higher quit rate, compared to a condition where the quitline assists the smokers to obtain patches by other means (e.g. via their health plans). 2. Test if sending placebo patches directly will also lead to a higher quit rate. 3. Test if quitline counseling increases the quit rate when the smokers already receive the nicotine patches.
NCT00954096 ↗	Nicotine Patch, Blood Flow and Oxidative Stress Study	Completed	National Institutes of Health (NIH)	N/A	2002-10-01	This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT00954096 ↗	Nicotine Patch, Blood Flow and Oxidative Stress Study	Completed	University of Pennsylvania	N/A	2002-10-01	This study will address the hypothesis that nicotine, like cigarette smoking acting as a pro-oxidant may have adverse effects on arterial function.
NCT00960778 ↗	Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes	Completed	Medical University of South Carolina	Phase 2	2009-03-01	This study will investigate the underlying neurobiology of differences between male and female smokers. Research suggests that women are less responsive to nicotine replacement therapy (NRT) than men and more responsive to the sensory and behavioral aspects of smoking. This study proposed that male smokers will have a greater response to NRT demonstrated by reduced withdrawal symptoms, craving, and less blood-oxygen-level dependent functional magnetic resonance imaging (BOLD FMRI) regional brain activation in response to nicotine-cues as compared to female smokers treated with NRT. Additionally, female smokers will have a greater response to denicotinized cigarettes with decreased withdrawal symptoms, craving, and less BOLD fMRI activation in response to nicotine-cues as compared to male smokers.
NCT01145001 ↗	Enhancing a High School Based Smoking Cessation Program	Completed	National Institute on Drug Abuse (NIDA)	N/A	2009-11-01	The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.
NCT01145001 ↗	Enhancing a High School Based Smoking Cessation Program	Completed	National Institutes of Health (NIH)	N/A	2009-11-01	The purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (CM) + cognitive behavioral therapy intervention. Subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either CM or no CM; all subjects will receive cognitive behavioral therapy. We hypothesize that that subjects receiving both active nicotine patch and CM will have higher rates of abstinence from tobacco than subjects in the other groups.

Clinical Trial Conditions for HABITROL

Condition Name

Condition Name for HABITROL
Intervention	Trials
Smoking Cessation	6
Nicotine Dependence	2
Psychiatric Illness	1
Sarcoidosis	1

Condition MeSH

Condition MeSH for HABITROL
Intervention	Trials
Tobacco Use Disorder	2
Sarcoidosis, Pulmonary	1
Sarcoidosis	1
Mental Disorders	1

Clinical Trial Locations for HABITROL

Trials by Country

Trials by Country for HABITROL
Location	Trials
United States	10
Canada	1

Trials by US State

Trials by US State for HABITROL
Location	Trials
California	3
Ohio	1
Illinois	1
Connecticut	1
South Carolina	1

Clinical Trial Progress for HABITROL

Clinical Trial Phase

Clinical Trial Phase for HABITROL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for HABITROL
Clinical Trial Phase	Trials
Completed	10
Not yet recruiting	1

Clinical Trial Sponsors for HABITROL

Sponsor Name

Sponsor Name for HABITROL
Sponsor	Trials
University of California, San Diego	3
California Department of Health Services	2
National Institutes of Health (NIH)	2

Sponsor Type

Sponsor Type for HABITROL
Sponsor	Trials
Other	17
NIH	4
U.S. Fed	1